Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim

Evotec AG / Key word(s): Alliance

05.06.2012 / 07:27

---------------------------------------------------------------------

Hamburg, Germany - 05 June 2012: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that its research alliance with Boehringer
Ingelheim has reached a milestone triggering a payment of EUR 4.0 million
to Evotec. The milestone was for the transition of a respiratory programme
into pre-clinical development.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: 'This is the
sixteenth milestone achieved as part of our alliance with Boehringer
Ingelheim and represents an important transition of this programme into
pre-clinical development.  The alliance continues to achieve significant
scientific and commercial success, reflecting the truly collaborative
efforts of teams from Evotec and Boehringer Ingelheim.'

ABOUT THE EVOTEC & BOEHRINGER INGELHEIM ALLIANCE
In 2004, Evotec entered into a multi-year, multi-target drug discovery
alliance with Boehringer Ingelheim to jointly identify and develop
pre-clinical development candidates for the treatment of various disease
areas including CNS, inflammation, cardiometabolic and respiratory
diseases. In 2009, the collaboration was extended for an additional four
years and the scope expanded to include oncology targets. Under the terms
of the agreement, Boehringer Ingelheim has full ownership and global
responsibility for clinical development, manufacturing and
commercialisation of the compounds identified. In return, Evotec receives
ongoing research payments and pre-clinical milestones. Furthermore, the
contract provides substantial long-term upside for Evotec through potential
payments for successful milestone achievements during clinical development
and royalties when new drugs reach the market.

Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
werner.lanthaler@evotec.com

FORWARD LOOKING STATEMENTS - Information set forth in this press
release contains forward-looking statements, which involve a number of
risks and uncertainties. The forward-looking statements contained herein
represent the judgement of Evotec as of the date of this report. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.


End of Corporate News

---------------------------------------------------------------------

05.06.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                
Company:     Evotec AG                                              
             Manfred Eigen Campus / Essener Bogen 7                 
             22419 Hamburg                                          
             Germany                                                
Phone:       +49 (0)40 560 81-0                                     
Fax:         +49 (0)40 560 81-222                                   
E-mail:      info@evotec.com                                        
Internet:    www.evotec.com                                         
ISIN:        DE0005664809                                           
WKN:         566480                                                 
Indices:     TecDAX                                                 
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,  
             München, Stuttgart                                     
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
172797 05.06.2012